Artesunate Resistance - An Emerging Threat

Area of Science:

• Tropical Medicine
• Infectious Diseases
• Parasitology

Background:

• Drug-resistant malaria poses a significant public health challenge in developing nations, particularly India.
• Artemisinin-based combination therapy (ACT) is the cornerstone of malaria treatment, but emerging resistance threatens its efficacy.
• Previous reports indicate partial artemisinin resistance and mutations in molecular markers across various Indian states.

Observation:

• Four cases of complicated Plasmodium falciparum malaria with apparent treatment failure following artemisinin-based therapy were observed in Eastern India between January 2020 and July 2021.
• Patients presented with severe symptoms including seizures, black stools, decreased urination, hematuria, and bleeding, with high parasite levels (30-45%).
• Despite initial treatment with injectable artesunate followed by oral ACT, parasite persistence was noted after 4 days, necessitating a switch to injectable quinine and clindamycin.

Findings:

• Microscopic parasite clearance was achieved by day 7 in all cases after switching to quinine and clindamycin.
• Two patients recovered fully, while two others developed multiorgan dysfunction, septic shock, and succumbed to the illness.
• Artemisinin resistance could not be definitively confirmed due to the unavailability of gene testing facilities in the study area.

Implications:

• The study underscores the critical need for enhanced surveillance systems to detect and monitor artemisinin resistance in India.
• Early identification of resistance is crucial for guiding clinicians in the selective use of antimalarial drug combinations.
• Implementing robust monitoring strategies will help preserve the effectiveness of artemisinin-based therapies and improve malaria treatment outcomes.